Glostrup, Denmark – January 12, 2014 – Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Cell Signaling Technology (CST), a worldwide provider of antibodies, today announced that they have entered into a strategic partnership to supply antibodies for use in Dako-branded companion diagnostics products.
"We are pleased to work with CST in the development of high-quality, cutting-edge companion diagnostic products that will be an important tool in the diagnosis and treatment of cancer," said Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group.
The market for companion diagnostics is steadily growing, as personalized medicine may improve patient care and assist in managing healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies, particularly in the treatment of cancer.
Today’s announcement follows several other collaborative agreements in the companion diagnostics area. Agilent’s Dako business has a record of successful long-term partnerships with companies such as Pfizer, AstraZeneca, Bristol-Myers Squibb, Merck & Co., Amgen and Eli Lilly, and it continues to attract new partners.
“CST recognizes that companion diagnostic products have great potential to improve the way we diagnose and treat patients with cancer,” said Michael J. Comb, CEO of CST. “We believe this partnership will allow our products to contribute to the advancement of personalized medicine.”
The financial details of the agreement were not disclosed.
Founded by research scientists in 1999, CST is a private, family-owned company with over 400 employees worldwide. Active in the field of applied systems biology research, particularly as it relates to cancer, CST understands the importance of using antibodies with high levels of specificity and lot-to-lot consistency. We produce all of our antibodies in house, and perform painstaking validations for multiple applications. Technical support is provided by the same CST scientists who produce our antibodies, helping customers design experiments, troubleshoot, and achieve reliable results. CST is certified by BSI to be compliant with ISO 9001:2008 for the design, development, and production of monoclonal antibodies. Information about CST is available at www.cellsignal.com.
Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of $4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. In 2012, Agilent acquired Dako, a well-known provider of reagents, instruments, software and expertise to make accurate diagnoses and determine the most effective treatment for cancer patients. Information about Agilent is available at www.agilent.com and information about Dako products is available at www.dako.com.
Editorial Contacts:
Agilent Media and Press
Maia Fredtoft Søchting
Phone: +45 2546 1083
Email: maia.sochting@agilent.com
CST Media and Press
Rebecca J. Reppucci
Cell Signaling Technology, Inc.
Director of Marketing Communications
phone: +1-978-867-2382
email: marketingpr@cellsignal.com
Cell Signaling Technology®, and CST™ are trademarks of Cell Signaling Technology, Inc.
